Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease
There is no age limit, gender is not limited
Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.
Patients with incomplete data or other factors affecting the clinical outcome judgement
Patients who are judged by the investigator to be unsuitable to participate in this study.
Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.
Other
Retrospective
Not listed
Clinical success rate
Clinical success incudes cure or symptom improvement，which means patients are alive, IFD-related symptoms and signs, radiographic abnormalities improve or disappear completely, and microbiological evidence suggests fungal clearance. The proportion of patients with cured or improved symptoms in the total population was analyzed.
Safety of amphotericin B and azoles
Safety evaluation was mainly based on the incidence of adverse events / adverse reactions in the two groups of patients.
Click on the lead sponsor to view all of their trials.
